Core Viewpoint - Co-Diagnostics, Inc. (CODX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, suggesting that upward revisions in earnings estimates can lead to higher stock valuations [4][6]. - CoDiagnostics is expected to earn -$0.91 per share for the fiscal year ending December 2025, reflecting a year-over-year change of 26.6% [8]. Analyst Sentiment and Market Position - Analysts have increased their earnings estimates for CoDiagnostics, with the Zacks Consensus Estimate rising by 22.2% over the past three months [8]. - The upgrade to Zacks Rank 2 places CoDiagnostics in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10].

Company Performance - Co-Diagnostics, Inc. reported a quarterly loss of $0.36 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.34, but an improvement from a loss of $0.50 per share a year ago, indicating a year-over-year improvement in loss figures [1] - The company posted revenues of $0.15 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 60.79%, and a significant decline from year-ago revenues of $3.56 million [2] - Over the last four quarters, Co-Diagnostics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Co-Diagnostics shares have declined approximately 44.5% since the beginning of the year, contrasting with the S&P 500's decline of 2.9%, indicating significant underperformance in the market [3] - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $0.4 million, and for the current fiscal year, it is -$1.17 on revenues of $1.5 million [7] Industry Outlook - The Medical Services industry, to which Co-Diagnostics belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a relatively strong position within the market [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Co-Diagnostics' stock performance [5]

Co-Diagnostics, Inc. (NASDAQ:CODX) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Andrew Benson - IR Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Operator Good day, and welcome to the Co-Diagnostics Fourth Quarter and Full Year 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, that this event ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION CO-DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Washington, D.C. 20549. Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_______to_______ Commission File Number 001-38148 (I.R.S. Employer Identification Numbe ...

Exhibit 99.1 Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results SALT LAKE CITY, March 27, 2025— Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Financial Results: Full Year 2024 and Recent Business Highlights: ● Revenue of $3.9 million, which declined from $6.8 million during the prio ...

SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024.Full Year 2024 Financial Results: Revenue of $3.9 million, which declined from $6.8 million during the prior year primarily due to higher Grant revenue in 2023. Grant revenue totaled $3.1 million while product revenue ...

SALT LAKE CITY, March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2024 results on Thursday, March 27, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts.  Management on the call will include Dwight ...

Core Viewpoint - Co-Diagnostics, Inc. achieved a complete dismissal of a securities class action lawsuit, which was a significant legal victory for the company [1][5][6]. Legal Proceedings - The lawsuit was initiated by Gelt Trading, Ltd. on June 15, 2020, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 against Co-Diagnostics and certain directors and officers [2]. - The case centered around a May 1, 2020, press release claiming that the Logix Smart® COVID-19 test had "100% sensitivity and 100% specificity," which the plaintiff argued was misleading and caused artificial inflation of the stock price [3]. Court Rulings - BakerHostetler, the legal firm representing Co-Diagnostics, successfully argued for summary judgment, asserting that the plaintiff could not prove any material fact supporting liability for the Section 10(b) claim [4]. - On March 4, 2025, the court granted the defendants' motion to exclude the plaintiff's expert testimony on loss causation and ruled that the plaintiff failed to demonstrate that the May 1 press release caused any losses [5]. Company Outlook - Following the dismissal, Co-Diagnostics expressed optimism about the potential for prevailing in any appeal and aims to focus on its mission of enhancing the availability of high-quality molecular diagnostics globally [6]. Company Profile - Co-Diagnostics, Inc. is a molecular diagnostics company based in Utah, specializing in the development, manufacturing, and marketing of advanced diagnostic technologies, particularly those involving nucleic acid detection and analysis [7].

Core Viewpoint - Co-Diagnostics, Inc. and CoSara Diagnostics Pvt. Ltd. are hosting a symposium on March 4, 2025, to raise awareness about HPV and its link to cancer, coinciding with International HPV Awareness Day [1][2] Group 1: Symposium Details - The symposium titled "HPV and Cancer: Exploring Advances in Prevention and Care" will feature speakers from Co-Dx, CoSara, and experts in cancer diagnostics and oncology from India [2] - The event aims to educate the public about HPV, reduce stigma, and empower individuals to take action against the virus [2] Group 2: Cancer Statistics and Impact - The National Cancer Institute estimates that high-risk HPV subtypes are responsible for approximately 5% of all cancers globally, including cervical cancer, which caused an estimated 350,000 deaths in 2022 [3] - About 94% of cervical cancer deaths occur in low- and middle-income countries (LMICs), where access to diagnostics, vaccinations, and screenings can significantly reduce mortality [3] Group 3: Co-Diagnostics' Initiatives - Co-Diagnostics is completing the assay development for its HPV multiplex test, designed to identify 8 high-risk HPV subtypes from cervical swab samples, aiming to provide an affordable screening tool for patients, especially in LMICs [4] - The CEO of Co-Dx emphasized the importance of early diagnosis in effective treatment and limiting the spread of HPV [5] - CoSara's Saragene® Human Papillomavirus-High Risk real-time PCR test has been cleared for use in India to detect high-risk HPV genotypes [5]

Core Viewpoint - Co-Diagnostics, Inc. has withdrawn its 510(k) application for the Co-Dx™ PCR COVID-19 Test based on FDA feedback regarding shelf-life stability, opting to submit an enhanced version of the test instead [1][3]. Group 1: FDA Interaction and Submission Withdrawal - The decision to withdraw the submission was made after discussions with the FDA concerning the detection of potential deterioration of a test component related to shelf-life stability [3]. - Co-Diagnostics expressed satisfaction with the productive engagement with the FDA regarding the initial regulatory submission and the test's performance in clinical evaluations [2][3]. Group 2: Future Plans and Enhancements - The company plans to submit the next iteration of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance after collecting clinical evaluation data to support the new test's performance [4]. - The new submission will allow the incorporation of recent developments in the Co-Dx PCR platform, aiming to enhance operational and manufacturing efficiencies [4]. - Co-Diagnostics aims to execute a robust development and commercialization plan for the Co-Dx PCR platform, with additional tests for tuberculosis, upper-respiratory multiplex, and multiplex HPV tests expected to follow [5]. Group 3: Company Overview - Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets advanced diagnostic technologies, utilizing proprietary technology for tests designed to detect and analyze nucleic acid molecules [7].